SEC Form 4 · accession 0000880771-15-000042
SCICLONE PHARMACEUTICALS INC · SCLN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Friedhelm Blobel
Officer — President & CEO
Period of report
Mar 16, 2015
Accepted (ET)
Mar 18, 2015 · 5:11 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000880771
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F1,F2 | $8.83 | Mar 16, 2015 | A | 140,000 | A | — | Mar 16, 2025 | Common Stock | 140,000 | 140,000 | D |
| Restricted Stock UnitF1,F3,F4 | — | Mar 16, 2015 | A | 20,000 | A | — | — | Common Stock | 20,000 | 104,017 | D |
Explanation of responses
- F1Granted under the Issuer's 2005 Equity Incentive Plan.
- F225% of such shares vest from the date of grant and 2.0833% vests each month thereafter, provided that the Reporting Person continues to be employed by the Issuer.
- F3Each restricted stock unit represents the right to receive, at settlement, one share of common stock.
- F4Vesting for such RSUs will occur 25% on March 16, 2016, 25% on March 16, 2017, 25% on March 16, 2018, and 25% on March 16, 2019, or on such later date thereafter as the Company's trading window opens, if it is not open on any of such dates, contingent upon the executive's continued employment.